Markets:

Overview

News

Currencies

International

Treasuries

ADMA Biologics Inc - Common Stock (NQ:ADMA)

9.090 -0.060 (-0.66%)

Streaming Delayed Price Updated: 1:12 PM EDT, Mar 31, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about ADMA Biologics Inc - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Why ADMA BIOLOGICS INC (NASDAQ:ADMA) qualifies as a high growth stock. ↗

April 23, 2025

A fundamental and technical analysis of (NASDAQ:ADMA): Is ADMA BIOLOGICS INC (NASDAQ:ADMA) suited for high growth investing?

Via Chartmill

Investors seeking growth at a reasonable cost should explore ADMA BIOLOGICS INC (NASDAQ:ADMA). ↗

April 16, 2025

Discover ADMA BIOLOGICS INC, an undervalued growth gem. NASDAQ:ADMA is shining in terms of growth metrics, and it's also displaying strong financial health and profitability, retaining an appealing...

Via Chartmill

ADMA Biologics Statement on Tariffs

April 07, 2025

Reiterates Strategic Advantage Through Fully U.S.-Based Manufacturing Operations, Commercialization and End-Market Sales, and Vertically Integrated U.S.-Based Supply Chain

From ADMA Biologics, Inc.

Via GlobeNewswire

What's Driving the Market Sentiment Around ADMA Biologics? ↗

April 02, 2025

Via Benzinga

What's Driving the Market Sentiment Around ADMA Biologics? ↗

March 11, 2025

Via Benzinga

Peering Into ADMA Biologics's Recent Short Interest ↗

January 22, 2025

Via Benzinga

How Is The Market Feeling About ADMA Biologics? ↗

December 30, 2024

Via Benzinga

Looking Into ADMA Biologics's Recent Short Interest ↗

December 05, 2024

Via Benzinga

ADMA BIOLOGICS INC (NASDAQ:ADMA) is showing good growth, while it is not too expensive. ↗

March 20, 2025

NASDAQ:ADMA is scoring great on several growth aspects while it also shows decent health and profitability. At the same time it remains remains attractively priced.

Via Chartmill

Adma Biologics' Retail Traders Eye Higher Open After Blowout Q4, Strong Full-Year Outlook ↗

March 03, 2025

CEO Adam Grossman highlighted a 65% year-over-year jump in total revenue and a staggering 309% increase in adjusted EBITDA for 2024.

Via Stocktwits

ADMA Biologics Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

March 03, 2025

From ADMA Biologics, Inc.

Via GlobeNewswire

Earnings Scheduled For March 3, 2025 ↗

March 03, 2025

Via Benzinga

ADMA Biologics to Participate in the Raymond James Institutional Investor Conference

February 28, 2025

From ADMA Biologics, Inc.

Via GlobeNewswire

ADMA Biologics to Report Fourth Quarter and Full Year 2024 Financial Results on March 3, 2025

February 25, 2025

Conference Call Scheduled for March 3, 2025, at 4:30 p.m. ET

From ADMA Biologics, Inc.

Via GlobeNewswire

Top 5 Biotech Stocks That Got Most Retail Buzz Last Week ↗

February 17, 2025

From merger updates to earnings surprises, these healthcare stocks saw the biggest spike in Stocktwits chatter.

Via Stocktwits

Jim Cramer Likes This Tech Stock: 'Terrific Business, Niche Business' ↗

January 30, 2025

On CNBC's "Mad Money Lightning Round," Jim Cramer recommended buying Keysight Technologies calling it a "Terrific business."

Via Benzinga

There May Still Be Time to Get in on These 3 Trending Biotechs

January 20, 2025

Biotech firms as a group declined slightly in the last year amid a tough external environment, but these three companies could grow in 2025.

Via MarketBeat

Topics ETFs Economy

SpringWorks Therapeutics Stock Sees RS Rating Jump To 86 ↗

January 13, 2025

On Monday, SpringWorks Therapeutics stock hit a key technical milestone, seeing its Relative Strength Rating jump to 86.

Via Investor's Business Daily

ADMA Biologics Announces Preliminary Full Year 2024 Revenue and Provides Business Update

January 13, 2025

From ADMA Biologics, Inc.

Via GlobeNewswire

Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts. ↗

January 09, 2025

Biotech stocks have seen three years of sideways to down trading. But obesity drugs, AI and Trump 2.0 promise to shake things up.

Via Investor's Business Daily

Topics Artificial Intelligence Government

SpringWorks Therapeutics Stock Gets A RS Rating Lift ↗

January 08, 2025

The Relative Strength (RS) Rating for SpringWorks Therapeutics stock entered a higher percentile Wednesday, as it got a lift from 62 to 76.

Via Investor's Business Daily

ADMA Biologics to Participate in the J.P. Morgan Healthcare Conference on January 13, 2025

January 07, 2025

From ADMA Biologics, Inc.

Via GlobeNewswire

Arcellx Stock Earns 82 Relative Strength Rating ↗

December 27, 2024

Arcellx stock saw a welcome improvement to its Relative Strength (RS) Rating on Friday, with an upgrade from 79 to 82.

Via Investor's Business Daily

ADMA Biologics Announces Partial Paydown of Senior Term Loan Credit Facility

December 20, 2024

From ADMA Biologics, Inc.

Via GlobeNewswire

ADMA Biologics, Inc. Is Being Investigated For Securities Fraud And Investors With Losses Are Urged To Contact The Schall Law Firm

December 13, 2024

Via ACCESSWIRE

The Schall Law Firm Invites Shareholder Participation In An Inquiry Into ADMA Biologics Inc For Securities Law Violations

December 12, 2024

Via ACCESSWIRE

NewAmsterdam Pharma Stock Hits 90-Plus RS Rating ↗

December 11, 2024

NewAmsterdam Pharma stock saw a welcome improvement to its Relative Strength (RS) Rating on Wednesday, rising from 74 to 95.

Via Investor's Business Daily

10 Health Care Stocks With Whale Alerts In Today's Session ↗

December 02, 2024

Via Benzinga

BioNTech Stock Got A IBD RS Rating Lift ↗

November 14, 2024

A Relative Strength Rating upgrade for BioNTech ADR shows improving technical performance.

Via Investor's Business Daily

ADMA BIOLOGICS ALERT: Bragar Eagel & Squire, P.C. is Investigating ADMA Biologics, Inc. on Behalf of ADMA Biologics Stockholders and Encourages Investors to Contact the Firm

November 12, 2024

From Bragar Eagel & Squire

Via GlobeNewswire

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.